Telix is pioneering a new cancer modality

We are passionate about improving the quality of life for people with cancer and rare diseases. And we put our patients at the heart of everything we do.

With over 20 clinical trials underway worldwide across a range of diseases, Telix is at the forefront of theranostic drug development.

Telix clinical trials

Telix is pushing the frontiers of diagnostic and therapeutic nuclear medicine through a number of clinical trials, both company-sponsored and in collaboration with leading cancer centres around the globe.

Prostate cancer / PSMA

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
University of Linz Prostate CancerComparative study of 68Ga-PSMA-11 PET/CT and 18F-fluorocholine PET/CT in the detection of recurrence in prostate cancer patients after radical treatmentUniversity of LinzTLX591-CDxProstate CancerImagingIIICompleteAustria
Emory University Prostate Cancer

Study ID: NCT03762759
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer OutcomesEmory UniversityTLX591-CDxProstate CancerImagingIIRecruitingUS
ENHANCING

Study ID: ACTRN12619000720112
Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic prostate cancer.GenesisCareTLX591-CDxProstate CancerImagingIIRecruitingAustralia
Memorial Sloan Kettering Prostate Cancer

Study ID: NCT03204123
PSMA PET Imaging of Recurrent Prostate CancerMemorial Sloan Kettering Cancer CenterTLX591-CDxProstate CancerImagingIIRecruitingUS
NOBLE Registry

NOBLE Registry
The NOBLE Registry is collecting prospective, real-world clinical data on the use of Telix’s SPECT-based investigational imaging product TLX599-CDx (99m Tc-iPSMA)Telix and Oncidium FoundationTLX599-CDxProstate CancerImagingNARecruitingGlobal
ProstACT GLOBAL

Study ID: NCT04876651
177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, which Expresses PSMATelixTLX591Prostate CancerTherapyIIISites being preparedGlobal
ProstACT TARGET

Study ID: NCT05146973
External Beam Therapy with Theranostic Radioligand Therapy for Oligometastatic Prostate CancerTelixTLX591Prostate CancerTherapyIIRecruitingAustralia
ProstACT SELECT

Study ID: NCT04786847
177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry StudyTelixTLX591Prostate CancerTherapyIRecruitingAustralia
CUPID

Study ID: NCT04726033
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) (CUPID)TelixTLX592Prostate CancerTherapyIRecruitingAustralia
Emory Breast Cancer

Study ID: NCT04750473
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast CancerEmory UniversityTLX591-CDxLobular Breast CancerImagingIRecruitingUS

Kidney cancer / CAIX

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
ZIRCON

Study ID: NCT03849118
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (89ZR-TLX250)TelixTLX250-CDxKidney CancerImagingIIICompleteGlobal
ZIRDAC-JP

Study ID: NCT04496089
Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr- TLX250 in Subjects with RCC (ZIRDAC-JP)TelixTLX250-CDxKidney CancerImagingI/IICompleteJapan
STARLITE-1TBCMD Anderson Cancer CenterTLX250Kidney CancerTherapyIIPendingUS
STARLITE-2

Study ID: NCT05239533
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerMemorial Sloan Kettering Cancer CenterTLX250Kidney CancerTherapyIIRecruitingUS
OPALESCENCE

Study ID: NCT04758780
Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer PatientsInstitut Cancerologie de l’OuestTLX250-CDxTriple Negative Breast CancerImagingIIRecruitingFrance
PERTINENCE

Study ID: NCT04897763
Assessment of Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr- labeled girentuximab (89Zr-Girentuximab) in Patients with Non-Muscle-Invasive Bladder CancerInstitut Cancerologie de l’OuestTLX250-CDxNon-Muscle-Invasive Bladder CancerImagingICompleteFrance
ZiP-UP

Study ID: NCT05046665
A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer PatientsSouth Metropolitan Health ServiceTLX250-CDxBladder or Urothelial CancerImagingIRecruitingAustralia

Glioblastoma / LAT-1

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
IPAX-2

Study ID: NCT05450744
131I-TLX-101 for Treatment of Newly Diagnosed GlioblastomaTelixTLX101GlioblastomaTherapyI/IIRecruitingAustralia, New Zealand
IPAX-LinzTBCKepler University HospitalTLX101GlioblastomaTherapyIIRecruitingAustria

Bone marrow conditioning

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
TRALA

Study ID: 2015-002231-18
A Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL AmyloidosisUniversity Southampton Hospital NHS Foundation TrustTLX66AL-AmyloidosisTherapyI/IIaCompleteUK
GOSHTBCGreat Ormond Street HospitalTLX66Pediatric LeukemiaTherapyIIActiveUK

Lung & ovarian cancers

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
APOMAB

Study ID: ACTRN12620000622909
A Phase 1, Single-Centre, Non-Randomised, Open-Labelled, 2-Arm, Single Dose study of Chimeric Anti-La/SSB Antibody (APOMAB) Conjugated with 89Zirconium-Label (89Zr-APOMAB) as a Theranostic Imaging Agent Using ImmunoPET/CT in Patients with Advanced Lung or Ovarian CancerAusHealthAPOMABLung or Ovarian CancerImaging and TherapyIActiveAustralia

Compassionate use

Telix is often contacted to provide access to our products under compassionate use. We respect the treatment journey of the patient and the independence of healthcare professionals in making their treatment decisions. Telix tries to accommodate such requests whenever it is clinically, ethically and practically feasible to do so.

You can find Telix’s compassionate use policy here: